Anixa Biosciences (NASDAQ:ANIX) released its earnings results on Wednesday. The company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.02, Fidelity Earnings reports.
Shares of NASDAQ:ANIX traded up $0.05 during trading on Friday, hitting $4.38. 705 shares of the company were exchanged, compared to its average volume of 469,969. The stock has a market capitalization of $137.67 million, a PE ratio of -3.83 and a beta of 1.41. Anixa Biosciences has a fifty-two week low of $1.70 and a fifty-two week high of $8.09. The firm has a fifty day simple moving average of $4.32.
In related news, Director Emily Gottschalk purchased 10,000 shares of the stock in a transaction on Friday, April 23rd. The shares were purchased at an average price of $4.49 per share, with a total value of $44,900.00. Insiders have acquired a total of 30,000 shares of company stock worth $137,150 in the last ninety days. Insiders own 19.80% of the company’s stock.
About Anixa Biosciences
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus.
Featured Story: Bear Market
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.